• 1
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-730.
  • 2
    Ries LAG, Melbert D, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2005, based on November 2007 SEER data submission. Bethesda, MD: National Cancer Institute; 2008. Available at: Accessed December 2, 2008.
  • 3
    Bennett CL, Greenfield S, Aronow H, et al. Patterns of care related to age of men with prostate cancer. Cancer. 1991; 67: 2633-2641.
  • 4
    Greenfield S, Blanco DM, Elashoff RM, et al. Patterns of care related to age of breast cancer patients. JAMA. 1987; 257: 2766-2770.
  • 5
    Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA. 1986; 255: 3385-3390.
  • 6
    Hundahl SA, Menck HR, Mansour EG, et al. The National Cancer Data Base report on gastric carcinoma. Cancer. 1997; 80: 2333-2341.
  • 7
    Coburn NG, Guller U, Baxter NN, et al. Adjuvant therapy for resected gastric cancer—rapid, yet incomplete adoption following results of intergroup 0116 trial. Int J Radiat Oncol Biol Phys. 2008; 70: 1073-1080.
  • 8
    Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-IV-18.
  • 9
    Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute. Cancer. 1995; 76: 2343-2350.
  • 10
    Macdonald J, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DEFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction. Results of intergroup study INT-0116 (SWOG 9008) [abstract]. Proc Am Soc Clin Oncol. 2000; 19. Abstract 1.
  • 11
    Allum W, Cunningham D, Weeden S, for the UK NCRI Upper GI Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 998.
  • 12
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV–55-IV-61.
  • 13
    Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40: IV–49-IV-54.
  • 14
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 15
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
  • 16
    Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 17
    Punglia RS, Weeks JC, Neville BA, et al. Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women. Int J Radiat Oncol Biol Phys. 2006; 66: 56-63.
  • 18
    Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004; 94: 540-549.
  • 19
    Punglia RS, Weeks JC, Neville BA, et al. Radiation therapy after mastectomy between 1991 and 1999 in elderly women: response to clinical trial information. J Clin Oncol. 2006; 24: 3474-3482.
  • 20
    Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20: 3999-4005.
  • 21
    Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006; 296: 2683-2693.
  • 22
    Kozak KR, Moody JS. The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 517-521.
  • 23
    Kelsen DP. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: Intergroup 116. J Clin Oncol. 2000; 18: 32S-34S.
  • 24
    Macdonald JS, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008) [abstract]. In: 2004 Gastrointestinal Cancers Symposium Proceedings. Alexandria, VA: American Society of Clinical Oncology; 2004. Abstract 6.
  • 25
    Kassam Z, Lockwood G, O'Brien C, et al. Conformal radiotherapy in the adjuvant treatment of gastric cancer: review of 82 cases. Int J Radiat Oncol Biol Phys. 2006; 65: 713-719.
  • 26
    Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005; 63: 1279-1285.
  • 27
    Coburn NG, Govindarajan A, Law CH, et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol. 2008; 15: 500-507.
  • 28
    Macdonald JS. Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol. 2005; 90: 166-170.
  • 29
    Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys. 2002; 52: 283-293.
  • 30
    Leong CN, Chung HT, Lee KM, et al. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer J. 2008; 14: 269-275.
  • 31
    Riley G, Tudor C, Chiang YP, et al. Health status of Medicare enrollees in HMOs and fee-for-service in 1994. Health Care Financ Rev. 1996; 17: 65-76.
  • 32
    Riley GF, Potosky AL, Klabunde CN, et al. Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. JAMA. 1999; 281: 720-726.
  • 33
    Riley GF, Warren JL, Potosky AL, et al. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans. Med Care. 2008; 46: 1108-1115.